100 related articles for article (PubMed ID: 21576405)
21. Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma.
Qiang YW; Barlogie B; Rudikoff S; Shaughnessy JD
Bone; 2008 Apr; 42(4):669-80. PubMed ID: 18294945
[TBL] [Abstract][Full Text] [Related]
22. Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.
Morgan G
Blood Rev; 2010 Nov; 24 Suppl 1():S27-32. PubMed ID: 21126634
[TBL] [Abstract][Full Text] [Related]
23. Bortezomib in the front-line treatment of multiple myeloma.
Richardson PG; Mitsiades C; Schlossman R; Ghobrial I; Hideshima T; Munshi N; Anderson KC
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1053-72. PubMed ID: 18588451
[TBL] [Abstract][Full Text] [Related]
24. The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma.
Baumann P; Mandl-Weber S; Oduncu F; Schmidmaier R
Exp Cell Res; 2009 Feb; 315(3):485-97. PubMed ID: 19071109
[TBL] [Abstract][Full Text] [Related]
25. Management of relapsed and relapsed refractory myeloma.
Kastritis E; Mitsiades CS; Dimopoulos MA; Richardson PG
Hematol Oncol Clin North Am; 2007 Dec; 21(6):1175-215, x. PubMed ID: 17996594
[TBL] [Abstract][Full Text] [Related]
26. Captivating bortezomib: an active but still mysterious drug.
Di Raimondo F; Conticello C
Leuk Res; 2010 Apr; 34(4):411-2. PubMed ID: 19819547
[No Abstract] [Full Text] [Related]
27. Activity of thalidomide and lenalidomide in mantle cell lymphoma.
Richardson SJ; Eve HE; Copplestone JA; Dyer MJ; Rule SA
Acta Haematol; 2010; 123(1):21-9. PubMed ID: 19907157
[TBL] [Abstract][Full Text] [Related]
28. New drugs for myeloma.
Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K
Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058
[TBL] [Abstract][Full Text] [Related]
29. In vitro efficacy of cinnarizine against lymphoma and multiple myeloma.
Schmeel LC; Schmeel FC; Kim Y; Blaum-Feder S; Endo T; Schmidt-Wolf IG
Anticancer Res; 2015 Feb; 35(2):835-41. PubMed ID: 25667464
[TBL] [Abstract][Full Text] [Related]
30. Inactivation of CK1α in multiple myeloma empowers drug cytotoxicity by affecting AKT and β-catenin survival signaling pathways.
Manni S; Carrino M; Manzoni M; Gianesin K; Nunes SC; Costacurta M; Tubi LQ; Macaccaro P; Taiana E; Cabrelle A; Barilà G; Martines A; Zambello R; Bonaldi L; Trentin L; Neri A; Semenzato G; Piazza F
Oncotarget; 2017 Feb; 8(9):14604-14619. PubMed ID: 28099937
[TBL] [Abstract][Full Text] [Related]
31. Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo.
Michaelis M; Fichtner I; Behrens D; Haider W; Rothweiler F; Mack A; Cinatl J; Doerr HW; Cinatl J
Int J Oncol; 2006 Feb; 28(2):439-46. PubMed ID: 16391799
[TBL] [Abstract][Full Text] [Related]
32. Treatment of multiple myeloma: 2009 update.
Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
[TBL] [Abstract][Full Text] [Related]
33. Moving disease biology from the lab to the clinic.
Anderson KC
Cancer; 2003 Feb; 97(3 Suppl):796-801. PubMed ID: 12548578
[TBL] [Abstract][Full Text] [Related]
34. Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells.
Fujita T; Doihara H; Washio K; Ino H; Murakami M; Naito M; Shimizu N
Anticancer Drugs; 2007 Jul; 18(6):677-86. PubMed ID: 17762396
[TBL] [Abstract][Full Text] [Related]
35. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo.
Zhang L; Qian Z; Cai Z; Sun L; Wang H; Bartlett JB; Yi Q; Wang M
Am J Hematol; 2009 Sep; 84(9):553-9. PubMed ID: 19565649
[TBL] [Abstract][Full Text] [Related]
36. S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice.
Lentzsch S; Rogers MS; LeBlanc R; Birsner AE; Shah JH; Treston AM; Anderson KC; D'Amato RJ
Cancer Res; 2002 Apr; 62(8):2300-5. PubMed ID: 11956087
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
[TBL] [Abstract][Full Text] [Related]
38. The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/beta-catenin pathway.
Flahaut M; Meier R; Coulon A; Nardou KA; Niggli FK; Martinet D; Beckmann JS; Joseph JM; Mühlethaler-Mottet A; Gross N
Oncogene; 2009 Jun; 28(23):2245-56. PubMed ID: 19421142
[TBL] [Abstract][Full Text] [Related]
39. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.
Noborio-Hatano K; Kikuchi J; Takatoku M; Shimizu R; Wada T; Ueda M; Nobuyoshi M; Oh I; Sato K; Suzuki T; Ozaki K; Mori M; Nagai T; Muroi K; Kano Y; Furukawa Y; Ozawa K
Oncogene; 2009 Jan; 28(2):231-42. PubMed ID: 18850009
[TBL] [Abstract][Full Text] [Related]
40. Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma.
Jagannath S; Dimopoulos MA; Lonial S
Leuk Res; 2010 Sep; 34(9):1111-8. PubMed ID: 20472288
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
